Biotechnology
U.S. BioDefense is pleased to announce today that it has signed a 90 day option to license European Patent Application No. 02743434.9, and U.S. patent application 10/483,190 entitled 'Liver cell progenitor and use for the treatment of liver disease' and
02:02 Feb 23, 2005
BIOLASE Technology, Inc. , a medical technology company that develops, manufactures and markets lasers and related products focused on technologies for improved applications and procedures in dentistry and related specialties, today announced the signing
00:35 Feb 23, 2005
Dr. John Todd, President and CEO of ProtoKinetix, Inc. , is proud to announce that the first series of results showing the efficacy of chemically synthesized AFGP has shown a very efficient cell preservation viability on a delicate human cell line . At c
00:02 Feb 23, 2005
SciClone Pharmaceuticals, Inc. today reported results for the fourth quarter and full year ended December 31, 2004. For the fourth quarter 2004, revenues from the sale of ZADAXIN, SciClone's lead product, increased 17% to $5,985,000, compared to $5,104,0
23:35 Feb 22, 2005
OmniComm Systems, Inc. , a leader in the EDC marketplace, announced today that it has just released a way to efficiently manage and streamline the reporting process with the creation of a MedWatch form generation tool. The tool compiles all relevant pati
06:25 Feb 22, 2005
Datascope Corp. announced that its Board of Directors declared a quarterly cash dividend of $0.07 per share payable on April 5, 2005 to stockholders of record as of March 4, 2005.
04:25 Feb 22, 2005
On Thursday, March 3, Andre Terzic, MD, PhD, will open the annual meeting of the American Society for Clinical Pharmacology and Therapeutics in Orlando with a speech calling on the FDA to work with the leading societies focused on drug development and ap
03:35 Feb 22, 2005
Viropro Pharma Inc., a subsidiary of Viropro Inc. , today announced the appointment of Mr. Rinaldo Mancin to the position of Director, Business Development for Latin-America, based in Brasilia, Brazil. Effective immediately, Mr. Mancin will oversee all c
03:32 Feb 22, 2005
Eternal Technologies Group, Inc. today announced that the Chairman of the Company and 5 senior management team members have arrived in the United States to complete business goals for First Quarter 2005. The major goals of the trip will be as follows:
01:35 Feb 22, 2005
Larta Institute will work with Genzyme Corporation to help the company discover new technologies through its Network T2 Consortium of 17 leading Southern California research institutions.
01:05 Feb 22, 2005
Glycology, Inc. announced that, effective today, the Reverse Split of one share for ten shares approved by the Company, as well as the name change from QuickTV, Inc. to Glycology, Inc. has now been cleared by the NASD.
23:05 Feb 21, 2005
Biolipox, a Swedish research-intensive pharmaceutical company in respiratory and inflammatory diseases, announced today that it has successfully completed a new clinical study, evaluating the time-to-onset of effect of its new antihistamine treatment, NL
19:52 Feb 21, 2005
Discovery Laboratories, Inc. today announced that Robert J. Capetola, Ph.D., President and Chief Executive Officer of Discovery, will present an update on the Company's recent progress and upcoming milestones at the BIO CEO and Investor Conference held a
07:22 Feb 21, 2005
Canadian biotech company Advitech and the CHUL Research Center, CHULRC will carry out a research project to assess the potential of XP-828L for treatment of inflammatory bowel diseases. XP-828L is Advitech's main platform. It is a purified milk protein f
02:05 Feb 21, 2005
Biacore International AB announces today that it has appointed Mr. Terry Pizzie as Senior Vice President of Commercial Operations. Mr. Pizzie has over 20 years' experience in the life science industry and he will take responsibility for all of Biacore's
00:12 Feb 21, 2005
Biolipox:
20:12 Feb 20, 2005
Vitrolife:
19:52 Feb 20, 2005
Discovery Laboratories, Inc. , has announced that in response to additional interest, the previously reported Registered Direct Offering with purchase commitments totaling approximately $26.5 million has been extended to include an additional commitment
13:32 Feb 18, 2005
Callisto Pharmaceuticals, Inc. , a biopharmaceutical company primarily focused on the development of drugs to treat cancer and osteolytic bone disease, announced today that Dr. Donald Picker, Callisto Executive Vice President of Research and Development,
07:25 Feb 18, 2005
Lydall, Inc. today announced it will report its fourth quarter and year ended December 31, 2004 results before the market opens on Tuesday, March 1, 2005.
05:35 Feb 18, 2005
43859 - 43878 of 44966 Stories
<<
<
Next 20 Biotechnology
>
>>
Search News
Daily News
